...
首页> 外文期刊>Journal for ImmunoTherapy of Cancer >P03.10?Prevalence and prognostic role of FoxP3 regulatory T lymphocytes in cancer. A tissue microarray study on 20’000 cancers
【24h】

P03.10?Prevalence and prognostic role of FoxP3 regulatory T lymphocytes in cancer. A tissue microarray study on 20’000 cancers

机译:P03.10?Foxp3监管T淋巴细胞在癌症中的患病率和预后作用。组织微阵列研究> 20'000癌症

获取原文
           

摘要

Background Regulatory FoxP3 lymphocytes function as suppressors of T-cell activity. The clinical impact of high FoxP3 cell density in cancers is not fully understood, as some studies have linked high FoxP3 cell density to good prognosis and others to poor prognosis in tumor cohorts with associated clinical data. While some data suggest that these variable data are due to biological differences between tumor entities, it is also possible that methodological differences have caused these discrepancies. This study was undertaken to analyze the density of FoxP3 cells in various different cancer types by employing standardized methods. Materials and Methods Tissue microarrays and large sections made from 20,000 prostate, breast, colorectal, ovarian, pancreatic, bladder and stomach cancers were analyzed together with various normal and inflamed tissues by conventional brightfield FoxP3 immunohistochemistry. Samples were also analyzed by fluorescent multiplex immunohistochemistry to assess the fraction of Ki67 FoxP3 cells. Results Our results indeed suggested a variable role of FoxP3 cells in different tumor types. High FoxP3 density was linked to high Gleason grade (p=0.0003) and early biochemical recurrence (p0.0001) in 16923 prostate cancers, but to low tumor stage (p=0.027) and prolonged survival (p=0.0029) in 1341 breast cancers, and to low tumor stage (p0.0001) in 744 colorectal cancers. No significant associations were found to tumor phenotype in 549 ovarian, 574 pancreatic, 549 bladder and 346 stomach cancers. Multiplex fluorescence IHC analysis of FoxP3 and Ki67 revealed comparable fractions of proliferating FoxP3 cells in healthy tissues (average 12.3%, range 5.8–18.5%) and inflammatory conditions (average 7.6%, range 2.6–17.2%). Interestingly, the rate of Ki67 FoxP3 cells was markedly higher in 36 bladder cancers (average 14.2%, range 0–49.3%) suggesting active expansion of FoxP3 cells in cancer. Conclusions Our data demonstrate an inverse prognostic impact of the FoxP3 cell density in prostate and breast cancers. The increased proliferation rate of immune-regulatory FoxP3 cells in some bladder cancer is interesting in the light of the variable response of these tumors to immune checkpoint inhibitors. Disclosure Information T. Mandelkow: None. E. Bady: None. N.C. Blessin: None. C. Hube-Magg: None. R. Simon: None. G. Sauter: None. C. Fraune: None. M. Lennartz: None. K. M?ller: None. S.A. Weidemann: None. A.M. Luebke: None. D. H?flmayer: None. F. Büscheck: None.
机译:背景技术调节Foxp3淋巴细胞用作T细胞活性的抑制剂。高氧化物3细胞密度在癌症中的临床影响尚不完全理解,因为一些研究已经将高狐p3细胞密度与良好的预后和其他相关性与相关的临床数据的肿瘤队列预后差。虽然一些数据表明这些变量数据是由于肿瘤实体之间的生物差异,但方法论差异也可能导致这些差异。本研究通过采用标准化方法来分析各种不同癌症类型中Foxp3细胞的密度。通过传统的Brightfield Foxp3免疫组化分析了由常规和发炎的组织分析了由> 20,000前列腺,乳腺癌,乳腺癌,卵巢,卵巢,胰腺癌,膀胱和胃癌的组织微阵列和大部分。还通过荧光多重免疫组织化学分析样品以评估Ki67 FoxP3细胞的级分。结果我们的结果确实表明Foxp3细胞在不同肿瘤类型中的可变作用。高狐p3密度与高玻璃素(p = 0.0003)和早期生化复发(p <0.0001)在16923前列腺癌中连接,但在1341乳腺癌中延长肿瘤阶段(p = 0.027),延长存活率(p = 0.0029) ,并在744种结肠直肠癌中肿瘤阶段(P <0.0001)。在549个卵巢,574个胰腺,549膀胱和346胃癌中没有发现肿瘤表型没有显着的关联。 FoxP3和Ki67的多重荧光IHC分析显示了健康组织中增殖FoxP3细胞的相当分数(平均12.3%,5.8-18.5%)和炎症条件(平均为7.6%,范围为2.6-17.2%)。有趣的是,Ki67 Foxp3细胞的速率在36个膀胱癌症中显着较高(平均14.2%,范围0-49.3%),表明癌症中Foxp3细胞的活跃扩增。结论我们的数据显示了前列腺和乳腺癌中Foxp3细胞密度对逆预后的影响。在一些膀胱癌中增加免疫调节狐p3细胞的增殖率鉴于这些肿瘤对免疫检查点抑制剂的可变响应的感兴趣。披露信息T. Mandelkow:无。 E. Bady:没有。 N.C. Blessin:没有。 C. Hube-Magg:没有。 R. Simon:没有。 G. Sauter:没有。 C. Fraune:没有。 M. Lennartz:没有。 K. m?ller:没有。 S.A. Weidemann:没有。是。 Luebke:没有。 D. H?Flmayer:没有。 F.Büscheck:没有。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号